InsiderSignal.AI

InsiderSignal.ai

KALV - Kalvista Pharmaceuticals, Inc.

Insider Sale by Palleiko Benjamin L (CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Palleiko Benjamin L, serving as CEO at Kalvista Pharmaceuticals, Inc. (KALV), sold 9,550 shares at $20.22 per share, for a total transaction value of $193,066.00. Following this transaction, Palleiko Benjamin L now holds 462,577 shares of KALV.

This sale represents a 2.00% decrease in Palleiko Benjamin L's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, April 17, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 20, 2026, 3 days after the trade was made.

Kalvista Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Palleiko Benjamin L

CEO

Benjamin L. Palleiko is the Chief Executive Officer and Director of KalVista Pharmaceuticals, a position he has held since March 2024[[1]](https://fintool.com/app/research/companies/KALV/people/benjamin-l-palleiko). He brings over 25 years of life sciences industry experience, including roles as a senior investment banker at Robertson Stephens and SunTrust, and as SVP & CFO of public biotech companies including Ore Pharmaceutical Holdings and Penwest Pharmaceuticals[[2]](https://www.kalvista.com/about/board-of-directors/). Palleiko holds a B.A. in Quantitative Economics from Tufts University and an M.B.A. in Finance and M.A. in International Relations from the University of Chicago, and previously served as a U.S. Navy Naval Aviator[[1]](https://fintool.com/app/research/companies/KALV/people/benjamin-l-palleiko). He joined KalVista as Chief Financial Officer in August 2016, was promoted to Chief Business Officer in 2019, and became President in 2023 before ascending to CEO[[1]](https://fintool.com/app/research/companies/KALV/people/benjamin-l-palleiko)[[2]](https://www.kalvista.com/about/board-of-directors/). Under his leadership as CEO, KalVista achieved significant regulatory and commercial milestones in fiscal year 2025, including FDA approval of EKTERLY (sebetralstat) in the U.S., UK marketing authorization, a positive CHMP opinion in the EU, and commercialization partnerships in Japan with Kaken and Canada with Pendopharm valued at $11 million in upfront payments plus additional milestones and royalties[[1]](https://fintool.com/app/research/companies/KALV/people/benjamin-l-palleiko). As of August 2025, Palleiko held beneficial ownership of approximately 948,980 shares (1.9% of outstanding shares) in KalVista[[1]](https://fintool.com/app/research/companies/KALV/people/benjamin-l-palleiko). His compensation structure reflects his executive role, with a base salary of $661,800 and a target bonus of 60% of base salary as of March 2024[[1]](https://fintool.com/app/research/companies/KALV/people/benjamin-l-palleiko).

View full insider profile →

Trade Price

$20.22

Quantity

9,550

Total Value

$193,066.00

Shares Owned

462,577

Trade Date

Friday, April 17, 2026

4 days ago

SEC Filing Date

Monday, April 20, 2026

Filed 3 days after trade

HEALTHCAREBIOTECHNOLOGY

About Kalvista Pharmaceuticals, Inc.

Company Overview

No company information available
View news mentioning KALV

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5810448

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime